文献速递甲状腺核医学核素与放射性配体治疗放射性药物与辐射防护

放射性碘治疗对儿童分化型甲状腺癌成年幸存者唾液腺功能的长期影响

Long-term effects of radioiodine treatment on salivary gland function in adult survivors of pediatric differentiated thyroid carcinoma.
PubMed 文献 · J Nucl Med · 2018-11-30

中位累积131I活度为5.88 GBq,47.7%接受多次给药。唾液腺功能障碍发生率为47.6%,中重度口干症为35.5%,且刺激性唾液分泌降低和口干症状加重与更高累积131I活度相关。

要点

  • 儿童DTC幸存者中唾液腺功能障碍发生率47.6%,中重度口干症35.5%。
  • 刺激性唾液分泌降低和口干症状加重与更高累积131I活度相关。
  • 唾液淀粉酶和总蛋白水平降低提示唾液腺分泌功能受损。

核心结论

  • 儿童DTC幸存者中临床显著唾液腺功能障碍发生率为35.5%,且与累积131I活度相关。

研究设计与样本

  • 全国性横断面研究纳入1970至2013年间治疗的儿童DTC患者,评估时距诊断>5年且年龄≥18岁。
  • 唾液腺功能通过唾液流率测定、唾液化学分析和口干症问卷评估。
  • 唾液腺功能障碍定义为非刺激性全唾液流率≤0.2 mL/min和/或刺激性全唾液流率≤0.7 mL/min。

主要发现

  • 中位累积131I活度5.88 GBq(IQR 2.92-12.95),47.7%接受多次131I给药。
  • 30例(47.6%)存在唾液腺功能障碍,唾液淀粉酶和总蛋白水平降低。
  • 22例(35.5%)存在中重度口干症。
  • 更高累积131I活度组刺激性唾液分泌更低、口干症状更重。

关键数值与推荐

  • 唾液腺功能障碍判定标准:非刺激性全唾液流率≤0.2 mL/min和/或刺激性全唾液流率≤0.7 mL/min。

临床怎么用

  • 对儿童DTC幸存者应长期监测唾液腺功能与口干症状。
  • 累积131I活度较高的患者需加强唾液腺功能保护与随访。

局限性

  • 横断面设计无法确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pediatric differentiated thyroid cancer (DTC) is a rare disease. Initial treatment of DTC consists of a (near) total thyroidectomy and radioactive iodine (131I) therapy. Previous studies in adults showed that 131I treatment may result in a reduced salivary gland function. Studies regarding salivary gland function in children treated for DTC are sparse. Our aim was to assess long-term effects of 131I treatment on salivary gland function in survivors of pediatric DTC. Methods: In a nationwide cross-sectional study, salivary gland function of patients treated for pediatric DTC between 1970 and 2013 (>5 years after diagnosis, ≥18 years old at time of evaluation) was studied. Salivary gland function was assessed by sialometry, sialochemistry and a xerostomia inventory. Salivary gland dysfunction was defined as unstimulated whole saliva flow ≤0.2mL/min and/or a stimulated whole saliva flow ≤0.7 mL/min. Results: Sixty-five patients (median age at evaluation 33 [IQR, 25-40] years, 86.2% female, median follow-up period 11 [IQR, 6-22] years) underwent 131I treatment. Median cumulative 131I activity was 5.88 [IQR, 2.92-12.95] GBq, 47.7% underwent multiple 131I administrations. Salivary gland dysfunction was present in 30 (47.6%) patients. Levels of amylase and total protein in saliva were reduced. Moderate to severe xerostomia was present in 22 (35.5%) patients. Stimulated salivary secretion was lower and severity of xerostomia complaints higher in patients treated with higher cumulative 131I activity. Conclusion: In survivors of pediatric DTC, clinically significant salivary gland dysfunction was found in 35.5% and was related to the cumulative 131I activity of the treatment.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Selvakumar T, Nies M, Klein Hesselink MS, et al. Long-term effects of radioiodine treatment on salivary gland function in adult survivors of pediatric differentiated thyroid carcinoma. J Nucl Med. 2018. PMID: 30504138. doi:10.2967/jnumed.118.212449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。